Company intelligence / Profile preview

NanoFCM

Ownership: Private
Development stage: Commercial

Overview

The company’s Flow NanoAnalyzer enables high-sensitivity and high-resolution multiparameter analysis of nanoparticles as small as 7 nm for metallic particles and 40 nm for biological entities. It supports applications in extracellular vesicle research, gene therapy development, vaccine formulation analysis, nanoparticle drug delivery systems characterization, and diagnostics. The technology has been adopted by leading biotech companies and academic institutions worldwide.

No clinical results are reported since the company provides analytical instrumentation rather than therapeutic products.

Modalities: DeviceNanoparticle
Industry: Drug Discovery Services

Partnerships

Academic researchers/universities & global biopharma clients

Beyond the preview

Go deeper on NanoFCM.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NanoFCM.

Explore the full profile